Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Landmark Purpose Program
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences, Inc. (NASDAQ:GILD) has announced the first Phase 2 clinical trial in Europe, PURPOSE 5, to evaluate an investigational long-acting HIV prevention option. The study will compare the use of lenacapavir with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who may benefit from pre-exposure prophylaxis (PrEP) and who are not currently taking PrEP. The trial will focus on recruiting participants from groups in France and the UK that are disproportionally affected by HIV and often underrepresented in clinical trials.
October 18, 2023 | 7:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gilead Sciences is launching a Phase 2 clinical trial for lenacapavir, a potential long-acting HIV prevention option. This could potentially expand Gilead's product portfolio and reach in the HIV prevention market.
The announcement of a new clinical trial for a potential HIV prevention option indicates Gilead's ongoing commitment to expanding its product portfolio in the HIV market. If successful, this could potentially increase Gilead's market share and revenues in the future. However, the outcome of the trial is uncertain and will take time to materialize.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100